SCHEMBL3563653

SCHEMBL3563653

Cc1cc(C(C)(C)CO)nc(-n2ccnc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 7/20 0.46
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CD38 P28907 6/20 0.38
CYP1A2 P05177 5/20 0.38
CYP2C19 P33261 2/20 0.38
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAP3K5 Q99683 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NOS1 P29475 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559939 0.86 NOS2 (0.46) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3573524 0.81 NOS2 (0.46) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3558930 0.80 NOS2 (0.43) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3559596 0.78 NOS2 (0.42) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL13037188 0.78 LMNA (0.50) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3558712 0.78 NOS2 (0.46) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL13037152 0.77 ALDH1A1 (0.42) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3568833 0.75 NOS2 (0.40) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3568834 0.75 NOS2 (0.40) NOS2KMT2ATDP1KDM4EALDH1A1
SCHEMBL3565421 0.73 ALDH1A1 (0.41) NOS2KMT2ATDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 NOS2 2/4885KMT2A 4248/4885TDP1 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.